NCT02667223终止1 期
A Phase 1, Open Label, Randomized, Single Dose, Dose Escalation Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab (pf 04950615) Alone And In Co Mixture With Recombinant Human Hyaluronidase (rhuph20, Pf 06744547) In Healthy And Hypercholesterolemic Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Pfizer
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Cmax of bococizumab
研究概览
简要总结
This is a Phase 1, open-label, single-dose, randomized, dose escalation study in healthy and hypercholesterolemic subjects. Each subject will receive 1 of 5 treatments as a single subcutaneous injection. Subjects will remain confined at the research clinic for approximately 2 days. After discharge, subjects will return to the research clinic 15 times during 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy and hypercholesterolemic subjects between the ages of 18 and 65 years.
- •Healthy subjects must have fasting LDL-C >/= 70 to </= 190 mg/dL at two qualifying visits.
- •Hypercholesterolemic subjects must be on a stable daily dose of statin for at least 45 days before dosing and fasting LDL-C must be >/= 70 mg/dL.
排除标准
- •Use of prescription or non-prescription drugs within 7 days or 5 half-lives (whichever) is longer prior to the first dose of study medication. For hypercholesterolemic subjects the use of statin class medication is allowed.
- •Prior exposure to bococizumab (also known as PF-04950615 or RN316) or other investigational PCSK9 inhibitors.
- •Treatment with monoclonal antibodies within 6 months or 5 half-lives (whichever is longer) before dosing.
结局指标
主要结局
Cmax of bococizumab
时间窗: Day 1 - Day 85
Maximum Observed Plasma Concentration (Cmax)
AUCinf of bococizumab
时间窗: Day 1 - Day 85
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞), if data permits (otherwise AUClast will be used).
次要结局
- AUEC85(Baseline up to Day 85)
- Laboratory tests(Baseline up to Day 85)
- LDL-C at Week 4(Baseline to Week 4)
- CL/F(Day 1 - Day 85)
- Vz/F(Day 1 - Day 85)
- Tmax, LDL-C(Baseline up to Day 85)
- AEs(Baseline up to Day 85)
- Vital signs(Baseline up to Day 85)
- AUClast of bococizumab(Day 1 - Day 85)
- ADA(Day 1 - Day 85)
- Tmax(Day 1 - Day 85)
- t1/2(Day 1 - Day 85)
- MaxELDL-C(Baseline up to Day 85)
- nAb(Day 1- Day 85)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular CarcinomaLiver CarcinomaHepatic Cell CarcinomaNCT06144385Shanghai Ming Ju Biotechnology Co., Ltd.20
招募中
1 期
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid TumorsHepatic Cell CarcinomaNCT06515314Shanghai Ruiliyuan Biotechnology Co., Ltd.12
已完成
1 期
Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisNCT06230822Wuhan Optics Valley Vcanbiopharma Co., Ltd.9
Unknown
1 期
An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells InjectionDiffuse Large B Cell LymphomaNCT04486872First Affiliated Hospital of Zhejiang University18
招募中
1 期
Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell LymphomaRelapsed or Refractory DLBCL Patients With Either CD19 or CD20 PositiveNCT04215016Fujian Medical University18